Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves β2-integrin-mediated interaction

Neoplasia

Volumn 11, Issue 7, 2009, Pages 662-671

  Sconocchia, Giuseppe ^a,b   Spagnoli, Giulio Cesare ^b   Del Principe, Domenico ^c   Ferrone, Soldano ^d   Anselmi, Maurizio ^b,c   Wongsena, Wachanan ^e   Cervelli, Valerio ^c   Schultz Thater, Elke ^b   Wyler, Stephen ^b   Carafa, Vincenza ^b   Moch, Holger ^f   Terracciano, Luigi ^b   Tornillo, Luigi ^b  

^a CNR   (Italy)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e NARESUAN UNIVERSITY   (Thailand)

^f UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 INTEGRIN; CASPASE; CD16 ANTIGEN; CD18 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CHLORDANE; HLA A ANTIGEN; HLA B ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL INFILTRATION; CELL INTERACTION; CELL MATURATION; CELL MEMBRANE; COCULTURE; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; EXOCYTOSIS; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY CARCINOMA; MACROPHAGE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; TARGET CELL; TISSUE MICROARRAY; TUMOR CELL;

EID: 67650472304     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09296     Document Type: Article

References (39)

1. Motzer RJ, Bander NH, and Nanus DM (1996). Renal-cell carcinoma. N Engl J Med 335, 865-875.
2. Motzer RJ and Russo P (2000). Systemic therapy for renal cell carcinoma. J Urol 163, 408-417.
3. Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, and Fefer A (1992). Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 10, 960-968.
4. Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T, and Takahashi K (1998). Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. Int J Urol 5, 16-21.
5. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linean WM, et al. (2000). Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343, 750-758.
6. Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Grone EF, Hohenfellner M, Haferkamp A, Pohla H, Schendel DJ, et al. (2006). Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 12, 718-725.
7. Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, and Storkel S (2003). Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res 9, 1721-1727.
8. Frankenberger B, Noessner E, and Schendel DJ (2007). Immune suppression in renal cell carcinoma. Semin Cancer Biol 17, 330-343.
9. Moretta A, Biassoni R, Bottino C, Mingari MC, and Moretta L (2000). Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 21, 228-234.
10. Kampbell KS and Colonna M (2001). Human natural killer cell receptors and signal transduction. Int Rev Immunol 20, 333-370.
11. Sconocchia G, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H, Hensel N, Melenhorst J, Li J, Ferrone S, et al. (2005). The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKD2D-target-cell interactions. Blood 106, 3666-3672.
12. Cerwenka A, Baron JL, and Lanier LL (2001). Ectotopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98, 11521-11526.
13. Kohler G and Milstein C (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497.
14. + cells cultured in interleukin-2 and stem cell factor generate a phenotypically novel monocyte. J Leukoc Biol 76, 1214-1219.
15. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Kimura R, Miyagi T, Mochizuki K, Sasaki Y, et al. (2003). Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 104, 354-361.
16. Sconocchia G, Del Principe D, and Barret AJ (2007). CD16 (low/negative) tumor-infiltrating lymphocyte: lymphoid or myeloid in origin? Clin Cancer Res 13, 1620.
17. + peripheral blood monocyte. Leukemia 19, 69-76.
18. Bruhns P, Marchetti P, Fridman WH, Vivier E, and Daeron M (1999). Differential roles of N- and C-terminal immunoreceptor tyrosine-based inhibition motifs during inhibition of cell activation by killer cell inhibitory receptors. J Immunol 162, 3168-3175.
19. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, and Spies T (1999). Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729.
20. Sutherland CL, Chalupny NJ, and Cosman D (2001). The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions. Immunol Rev 181, 185-192.
21. Chang CC, Campoli M, and Ferrone S (2004). HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr Opin Immunol 16, 644-650.
22. Doubrovina ES, Doubrovin MN, Vider E, Sisson RB, O'Reilly RJ, Dupont B, and Vyas YM (2003). Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 171, 6891-6899.
23. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, et al. (2005). HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105, 251-258.
24. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, and Spies T (1999). Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96, 6879-6884.
25. Ziegler-Heitbrock HW, Passlick B, and Flieger D (1988). The monoclonal anti-monocyte antibody My4 stains B lymphocytes and two distinct monocyte subsets in human peripheral blood. Hybridoma 7, 521-527.
26. + subpopulation. Immunol Today 17, 424-428.
27. high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol 25, 3418-3424.
28. + blood monocytes is expanded in sepsis patients. Blood 82, 3170-3176.
29. + monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood 85, 2910-2917.
30. + macrophages in antitumor cytotoxicity. Lab Invest 67, 166-174.
31. ++ monocytes are a major source of TNF. J Immunol 168, 3536-3542.
32. + monocytes in patients with myeloma and lymphoma. J Leukoc Biol 75, 207-213.
33. Melichar B, Touskova M, and Vesely P (2002). Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with matastatic colorectal cancer. Hepatogastroenterology 49, 967-970.
34. Allavena P, Sica A, Solinas G, Porta C, and Mantovani A (2008). The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66, 1-9.
35. Mantovani A, Romero P, Palucka AK, and Marincola FM (2008). Tumor immunity: effector response to tumor and role of the microenvironment. Lancet 371, 771-783.
36. + cells. J Clin Invest 116, 2777-2790.
37. Viola A and Bronte V (2007). Metabolic mechanisms of cancer-induced inhibition of immune responses. Semin Cancer Biol 17, 309-316.
38. 2 integrins: moderators of life or death decisions. Trends Immunol 26, 388-395.
39. Jewett A, Cacalano NA, Head C, and Teruel A (2006). Coengagement of CD16 and CD94 receptors mediates secretion of chemokines and induces apoptotic death of naive natural killer cells. Clin Cancer Res 12, 1994-2003.